Bayer's Patent Win Keeps $93 Billion Vaccine Question Alive as FDA Fast-Tracks Lynkuet

Bayer shares fell 3.7% as a Delaware judge kept its mRNA patent case alive, while the FDA granted priority review to Lynkuet.

Bayer shares are giving investors a bumpy ride this Tuesday, caught between a favorable courtroom development in the United States and a broader reassessment of how quickly the German group's pharmaceutical pipeline can offset its legacy legal burdens.

The DAX-listed stock was quoted at 50.98 euros in pre-market trading, up 38 percent since the start of the year. By the time regular trading got underway, the picture had darkened: the paper changed hands at 48.89 euros, a daily decline of 3.7 percent.

A Delaware Judge Declines to End the mRNA Fight

At the center of the day's news is a decision by US District Judge William Bryson in Delaware, who rejected motions from Pfizer, BioNTech and Moderna seeking early dismissal of a damages suit brought by Bayer. The ruling keeps alive a case that could ultimately be worth billions in licensing claims.

The dispute traces back to a complaint Bayer filed in January 2026. It hinges on US Patent 7,741,118, which Monsanto applied for in 1989 and which was granted in 2010. The technology was originally designed to stabilize mRNA in crops so plants could better fend off insect pests.

Bayer contends that Pfizer, BioNTech and Moderna relied on precisely that method to preserve the genetic material in their COVID-19 vaccines. According to the Leverkusen-based group, the Pfizer-BioNTech pair has acknowledged using such codon optimization in mRNA production. Comirnaty, the vaccine developed by those two partners, generated more than 93 billion US dollars in revenue.

The defendants counter that their manufacturing processes differ fundamentally from the described method. Moderna adds that the contested protection right describes a law of nature that cannot be patented. Judge Bryson found those arguments insufficiently substantiated at this stage, noting that the defendants had neither proven the patent's invalidity nor demonstrated that their products do not infringe its rights.

The decision improves Bayer's starting position for enforcing potential royalty demands, though it does not end the litigation. The case now moves into a deeper examination of the technical details.

A separate proceeding is running in New Jersey, where Bayer has accused Johnson & Johnson of using protected procedures in producing its vaccine. Progress in Delaware raises the odds that the group can still extract substantial financial returns from historical research conducted by its Monsanto subsidiary.

FDA Grants Priority Review for Lynkuet

On the regulatory front, the US Food and Drug Administration granted an accelerated review yesterday for Lynkuet, whose active ingredient is Elinzanetant. The priority review covers an additional indication for treating moderate to severe vasomotor symptoms in women undergoing endocrine therapy because of hormone receptor-positive breast cancer.

Such a classification noticeably shortens the agency's processing time and gives the group a chance to broaden the approved use of one of its most closely watched candidates faster than under the standard procedure. Lynkuet is regarded as a key building block because extending it to cancer patients on hormone therapy addresses a segment with high unmet medical need. Whether that step durably supports earnings depends on the actual conclusion of the FDA process — the mere granting of priority review is not a guaranteed approval.

MiraSOFT Hits CVS Shelves

In consumer health, Bayer announced today the sales launch of the stool softener MiraSOFT, which will be distributed through more than 7,000 branches of US pharmacy chain CVS as well as online. Successfully anchoring new over-the-counter products like MiraSOFT through established distribution channels in the US pharmacy market would steady the cash flow of the consumer health division.

Refinancing and the Roundup Overhang

Investors are also weighing how far the group's capital structure has already been strengthened. A little over a week ago, Bayer issued hybrid bonds worth more than 2 billion euros, while the share price has slipped 1.3 percent since then. Management is using such steps to secure financial headroom, but operating earnings momentum must keep pace with the refinancing effort.

Roughly two weeks ago, the company filed a settlement motion in the long-running Roundup complex — a move that, if legally approved, could gradually dismantle one of the stock's biggest valuation obstacles.

What Could Go Right — and What Could Go Wrong

In the optimistic scenario, Bayer converts the regulatory review of Lynkuet into a marketing authorization on schedule. A swift US launch would diversify the pharmaceutical business and reduce dependence on older blockbusters. Should the mRNA patent case against Pfizer, BioNTech and Moderna eventually produce substantial settlements or court-ordered royalties, extraordinary cash inflows would follow, sharply expanding financial flexibility.

The opposing scenario sees legal disputes dragging on and tying up considerable resources. Continuing the suits against the vaccine makers means additional procedural costs with no guarantee of success; if courts ultimately dismiss the claims on the merits, hopes for compensation evaporate entirely. There is also the risk that regulatory requirements delay pipeline candidates. Should the FDA demand revisions or extra safety data for Lynkuet despite the priority review, the hoped-for market launch would be pushed back. Add to that the pricing pressure and volatile demand in agricultural chemicals and consumer health, which can weigh on margins. As long as the burdens from earlier acquisitions are not fully cleared, the market reacts sensitively to any operational disappointment.

Chart Levels and the Catalysts Ahead

Technically, the recovery pattern of recent months remains intact as long as the share price holds above its 50-day moving average of 48.60 euros. A slide below that mark would cloud the chart picture and increase pressure on recent gains.

Concrete dates now matter for the broader direction. The next direct catalyst is the FDA's review result on the Lynkuet indication extension, with its completion date set under the priority review process. Investors must also track further rulings from the US federal court in the patent fight against Pfizer and BioNTech, along with the progress of the proposed Roundup settlement. These legal and regulatory milestones will largely determine whether the group can continue its fundamental revaluation.